NEWS |
COSMECEUTICAL REGULATION NEEDED
cosmeceutical products, which offer a way to keep up appearances without going under the knife, says a new report by market experts GBI Research. The report states that the market for
T
cosmeceuticals represents the fastest growing segment of today’s personal care industry. Demand is spiralling, driven mainly by anti-ageing products, which offer an alternate to cosmetic surgical procedures, which promise more dramatic results, but at a higher cost in terms of time, money and safety. Common
ingredients in cosmeceuticals include hydroxy acids such as salicylic acid, antioxidants such as vitamins C, and natural botanicals such as aloe vera, along with enzymes, hormones, and topical anaesthetics. Cosmeceuticals are not officially recognised
he global population grows older while increasing social pressures drive individuals to look younger, and consumer awareness has risen for
CONSUMERS SPEND BIG, BUT REGULATION NECESSARY
with regard to results. The consumer is often left to guess at associations between elaborate ingredients and purported outcomes. However, cosmeceuticals must adhere to specific regulations for Good Manufacturing Practices (GMP) to ensure that products are not misbranded. Product efficacy is scrutinised by the US Federal Trade Commission (FTC), and cosmeceutical products that are perceived to be promising unrealistic expectations may be pulled from the shelves.
Many cosmeceutical marketers include
ingredients which only
have anecdotal evidence of effect, and make no
direct claims with regard to results.
by the Food and Drug Administration (FDA), so while products are tested for safety by the manufacturer and the FDA, proof of the claimed therapeutic advantages is not demanded. Many cosmeceutical marketers include ingredients which only have anecdotal evidence of effect, and make no direct claims
Market expected to grow Cosmeceutical marketers must also adhere to guidelines set by the Federal Trade Commission (FTC) for product marketing, which censor exaggerated or false product claims. Misrepresentative advertising is a matter of constant debate in the beauty industry, with fake eyelashes used in mascara adverts and airbrushing applied to anti-wrinkle cream poster girls. The market is dominated by a small number of large players such as Procter & Gamble (P&G), L'Oreal, Unilever and Beiersdorf, who
attribute their success to building big brands such as Olay, L'Oreal, Garnier and Nivea with massive marketing budgets. The cosmeceuticals markets in the US, UK,
France, Germany, Italy, Spain and Japan were estimated to be worth $30.9 billion collectively in 2011, with the combined markets expected to reach $42.4 billion by 2018, following growth at a compound annual growth rate (CAGR) of 4.6%. Presently, cosmeceutical companies rely on developed nations, but increasing wealth in emerging markets such as Latin America, China and India is expected to see products reach out to
an even wider audience in future.
10 ❚ January/February 2013 |
prime-journal.com
AAD MIAMI MEETING UPDATE
Adverse cutaneous drug reactions occur in 2–3% of hospitalised patients. They are among the most common types of the 1.5 million preventable adverse drug events that occur annually in the US. David Adams, MD, PharmD, will direct the
session 'Adverse Drug Reactions: The Evidence and the Controversies' at AAD Miami from 3:30 to 5:30 pm on Sunday, March 3. The session will address gaps in knowledge
and competence in preventing, diagnosing, treating, and reporting adverse cutaneous drug reactions. 'Medications are highly used in the care of
dermatology patients and are also associated with more than 100 documented types of adverse effects to the skin, hair, and nails,' Dr Adams said. Cases of common — and less common, but
potentially severe — reactions will be presented to address gaps in quickly differentiating severe reactions from less serious reactions, and in initiating appropriate treatments when indicated. Gaps in pharmaceutical knowledge about particular drugs also will be addressed.
Minimising ADRs Dr Adams will discuss methods to improve competence in educating patients about the safe and effective use of medications, the importance of reporting adverse drug reactions, and reporting processes. 'Adverse drug reactions are — and will always
be — a part of the care of our patient population,' Dr Adams said. 'It is important as dermatologists to be aware of the potential risks of medications to minimise adverse drug effects and to be accurate in making timely and correct diagnoses to provide the best patient care. This is especially important with new medications being approved and used each year.' This session is ticketed, so be sure to register in advance if you plan to attend.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76